Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer

Cancer. 1989 Feb 1;63(3):438-9. doi: 10.1002/1097-0142(19890201)63:3<438::aid-cncr2820630307>3.0.co;2-o.

Abstract

High-dose megestrol acetate, a synthetic progestin, has been advocated recently in treating patients with metastatic breast carcinoma; no significant increase in adverse effects has been reported. This report describes a patient with jaundice and intrahepatic cholestasis after high-dose megestrol acetate therapy. This cholestatic lesion may have a pathogenesis similar to that observed with estrogens and oral contraceptives.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols*
  • Bilirubin / blood
  • Breast Neoplasms / drug therapy*
  • Cholestasis, Intrahepatic / chemically induced*
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Jaundice / chemically induced*
  • Mastectomy, Radical
  • Megestrol / administration & dosage
  • Megestrol / adverse effects
  • Megestrol / analogs & derivatives*
  • Megestrol Acetate
  • Methotrexate / administration & dosage
  • Prednisone / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Cyclophosphamide
  • Megestrol
  • Bilirubin
  • Megestrol Acetate
  • Fluorouracil
  • Prednisone
  • Methotrexate

Supplementary concepts

  • CMF regimen